Document is current

Article History

Received: 1 May 2025

Accepted: 25 July 2025

First Online: 11 August 2025

Declarations

:

: This study was approved by the local institutional review board (IRB-number: 36–030 ex 23/24). Given the retrospective design of the study, no written patient consent was obtained.

: N/A.

: MAS reports support for attending scientific meetings by implantcast, Alphamed Fischer, ImplanTec and PharmaMar, outside of the submitted work. FAW reports research support by the Foundation for Cardiovascular Research— Zurich Heart House, Kurt und Senta Herrmann Foundation, Theodor und Ida Herzog-Egli Stiftung, 4TEEN4 Pharmaceuticals GmbH, PAM Theragnostics GmbH, and Sphingotec GmbH, financial support by the Research Funding for excellent research by the University of Zurich, Fonds zur Förderung des akademischen Nachwuchses of the University of Zurich, Amgen Switzerland, European Society of Cardiology, Swiss Society of Cardiology, Swiss Heart Foundation, and Medical University of Graz, support for attending scientific meetings by 4TEEN4 Pharmaceuticals GmbH, PAM Theragnostics GmbH, Sphingotec GmbH, European Society of Cardiology, Swiss Society of Cardiology, Foundation for Cardiovascular Research— Zurich Heart House, and Critical Care Clinical Trialists Consortium, support in biomarker measurements by Roche Diagnostics, 4TEEN4 Pharmaceuticals GmbH, PAM Theragnostics GmbH, and Sphingotec GmbH, as well as membership in the Steering Committee of the National Registry of Acute Myocardial Infarction in Switzerland, outside of the submitted work. AL reports institutional educational grants by Alphamed, Medacta, and Johnson&Johnson, outside of the submitted work. The other authors report no conflicts of interest.